Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
Recruiting · NCT06219239 · Registry updated 2025-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, beta thalassemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, thalassemia | Recruiting | Not applicable | 2025-08-05 | NCT06219239 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
| Kanglin Biotech | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital | Tianjin | China | 24 |